Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Summit Therapeutics (SMMT) over the last 4 years, with Q3 2025 value amounting to $2.4 million.

  • Summit Therapeutics' Non Operating Income fell 4718.22% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 4609.43%. This contributed to the annual value of $13.4 million for FY2024, which is 1954.75% up from last year.
  • As of Q3 2025, Summit Therapeutics' Non Operating Income stood at $2.4 million, which was down 4718.22% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Non Operating Income ranged from a high of $16.1 million in Q4 2023 and a low of -$4.4 million during Q3 2022
  • In the last 4 years, Summit Therapeutics' Non Operating Income had a median value of $2.7 million in 2025 and averaged $3.5 million.
  • Over the last 5 years, Summit Therapeutics' Non Operating Income had its largest YoY gain of 68994.85% in 2024, and its largest YoY loss of 7255.34% in 2024.
  • Over the past 4 years, Summit Therapeutics' Non Operating Income (Quarter) stood at $5.5 million in 2022, then soared by 194.35% to $16.1 million in 2023, then crashed by 72.55% to $4.4 million in 2024, then crashed by 45.29% to $2.4 million in 2025.
  • Its Non Operating Income was $2.4 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.9 million in Q1 2025.